Adenoviral vectors expressing fusogenic membrane glycoproteins activated via matrix metalloproteinase cleavable linkers have significant antitumor potential in the gene therapy of gliomas

Journal of Gene Medicine

Volumn 6, Issue 11, 2004, Pages 1216-1227

  Allen, Cory ^a   McDonald, Cari ^a   Giannini, Caterina ^a   Peng, Kah Whye ^a   Rosales, Gabriela ^a   Russell, Stephen J ^a   Galanis, Evanthia ^a  

^a MAYO CLINIC   (United States)

Author keywords

Adenovirus; GALV; Gliomas; Linkers; MMP; Targeting

Indexed keywords

1,10 PHENANTHROLINE; ADENOVIRUS VECTOR; AMIDE; CD40 LIGAND; COXSACKIE VIRUS AND ADENOVIRUS RECEPTOR; GELATINASE A; GREEN FLUORESCENT PROTEIN; MATRIX METALLOPROTEINASE; MATRIX METALLOPROTEINASE INHIBITOR; SERINE PROTEINASE INHIBITOR; SOYBEAN TRYPSIN INHIBITOR; VIRUS ENVELOPE PROTEIN; VIRUS GLYCOPROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; ASTROCYTE; CANCER CELL CULTURE; CANCER SURVIVAL; CARBOXY TERMINAL SEQUENCE; CELL DEATH; CONTROLLED STUDY; CYTOTOXICITY; DOSE RESPONSE; ENZYME ACTIVITY; ENZYME ASSAY; ENZYME MECHANISM; EXTRACELLULAR MATRIX; GENE ACTIVATION; GENE CONSTRUCT; GENE EXPRESSION; GENE FUSION; GENE OVEREXPRESSION; GENE TARGETING; GENETIC LINKAGE; GLIOMA; GLIOMA CELL; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INTERMETHOD COMPARISON; INTERNAL RIBOSOME ENTRY SITE; MOUSE STRAIN; NONHUMAN; PRIORITY JOURNAL; PROTEIN DOMAIN; PROTEIN EXPRESSION; QUANTITATIVE ANALYSIS; STATISTICAL SIGNIFICANCE; SUBCUTANEOUS TISSUE TUMOR; SUPERNATANT; SYNCYTIUM; TUMOR REGRESSION; TUMOR XENOGRAFT; VIRAL GENE THERAPY; VIRUS CELL INTERACTION; VIRUS INFECTION; VIRUS REPLICATION; WESTERN BLOTTING; ZYMOGRAPHY;

ADENOVIRIDAE; ANIMALS; CELL COUNT; CELL DEATH; CELL FUSION; CELL LINE, TUMOR; CELL SIZE; GENE THERAPY; GENETIC VECTORS; GIANT CELLS; GLIOMA; HUMANS; LEUKEMIA VIRUS, GIBBON APE; MATRIX METALLOPROTEINASES; MEMBRANE GLYCOPROTEINS; MICE; TRANSPLANTATION, HETEROLOGOUS; VIRAL PROTEINS;

ADENOVIRIDAE; ALOCASIA MACRORRHIZOS; ANIMALIA; GIBBON APE LEUKEMIA VIRUS; GLYCINE MAX; HYLOBATES SP.; MUS MUSCULUS;

EID: 13644262373     PISSN: 1099498X     EISSN: 15212254     Source Type: Journal    
DOI: 10.1002/jgm.616     Document Type: Article

References (31)

1. Galanis E, Bateman A, Johnson K, et al. Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum Gene Ther 2001; 12: 811-821.
2. Bateman A, Bullough F, Murphy S, et al. Fusogenic membrane glycoproteins as a novel class of genes for the local and immune-mediated control of tumor growth. Cancer Res 2000; 60: 1492-1497.
3. Diaz RM, Bateman A, Emiliusen L, et al. A lentiviral vector expressing a fusogenic glycoprotein for cancer gene therapy. Gene Ther 2000; 7: 1656-1663.
4. Olah Z, Lehel C, Anderson WB, et al. The cellular receptor for gibbon ape leukemia virus is a novel high affinity phosphate transporter. J Biol Chem 1994; 269: 25 426-25 431.
5. Forestell SP, et al. Novel retroviral packaging cell lines: complementary tropisms and improved vector production for efficient gene transfer. Gene Ther 1994; 4: 600-610.
6. Morling FJ, Peng KW, Cosset F-L, et al. Masking of retroviral envelope functions by oligomerizing polypeptide adaptors. Virology 1997; 234: 51-61.
7. Peng K-W, Vile RG, Cosset F-L, et al. Selective transduction of protease-rich tumors by matrix-metalloproteinase-targeted retroviral vectors. Gene Ther 1999; 6: 1552-1557.
8. Johnson KJ, Peng KW, Allen C, et al. Targeting the cytotoxicity of fusogenic membrane glycoproteins in gliomas though protease-substrate interaction. Gene Ther 2003; 10: 725-732.
9. Nakada M, Nakamura H, Ikeda E, et al. Expression and tissue localization of membrane-type 1, 2 and 3 matrix metalloproteinases in human astrocytic tumors. Am J Pathol 1999; 154: 417-428.
10. Lampert K, Machein U, Machein MR, et al. Expression of matrix metalloproteinase and their tissue inhibitors in human brain tumors. Am J Pathol 1998; 153: 429-437.
11. Apodaca G, Rutka JT, Bouhara K, et al. Expression of metalloproteinases and metalloproteinase inhibitors by fetal astrocytes and glioma cells. Cancer Res 1990; 50: 2322-2329.
12. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res 1996; 56: 384-392.
13. Graham FL, Prevec L. Adenovirus-based expression vectors and recombinant vaccine. Biotechnology 1992; 20: 363-390.
14. Uhm JH, Dooley NP, Villemure JG, et al. Glioma invasion in vitro: regulation by matrix metalloprotease-2 and protein kinase C. Clin Exp Metastasis 1996; 14: 421-433.
15. Miller CR, Buschsbaum DJ, Reynolds PN, et al. Differential susceptibility of primary and established human glioma cells to adenovirus infection: targeting via the epidermal growth factor receptor achieves fiber receptor-independent gene transfer. Cancer Res 1998; 58: 5738-5748.
16. Fueyo J, Alemany R, Gomez-Manzano C, et al. Preclinical characterization of the antiglioma activity of a tropism-enhanced adenovirus targeted to the retinoblastoma pathway. J Natl Cancer Inst 2003; 95: 652-660.
17. Ye Q-Z, Johnson LL, Yu AE, et al. Reconstructed 19kDa catalytic domain of gelatinase A is an active proteinase. Biochemistry 1995; 34: 4702-4708.
18. Will H, Atkinson SJ, Butler GS, et al. The soluble catalytic domain of membrane type 1 matrix metalloproteinase cleaves the propeptide of progelatinase A and initiates autocatalytic activation. J Biol Chem 1996; 271: 17 119-17 123.
19. Emiliusen L, Gough M, Bateman A, et al. A transcriptional feedback loop for tissue-specific expression of highly cytotoxic genes which incorporates an immunostimulatory component. Gene Ther 2001; 8: 987-998.
20. Higuchi H, Bronk SF, Bateman A, et al. Viral fusogenic membrane glycoprotein expression causes syncytia formation with bioenergetic cell death: Implications for gene therapy. Cancer Res 2000; 60: 6396-6402.
21. Johann SV, Gibbons JJ, O'Hara B. GLVR1, a receptor for gibbon ape leukemia virus, is homologous to a phosphate permease of Neurospora crassa and is expressed at high levels in the brain and thymus. J Virol 1992; 66: 1635-1640.
22. Kavanaugh MP, Miller DG, Zhang W, et al. Cell-surface receptors for gibbon ape leukemia virus and amphotropic murine retrovirus are inducible sodium-dependent phosphate symporters. Proc Natl Acad Sci U S A 1994; 91: 7071-7075.
23. Palmer G, Manen D, Bonjour JP, et al. Characterization of the human Glvr-1 phosphate transport/retrovirus receptor gene and promoter region. Gene 1999; 226: 25-33.
24. Brade AM, Szmitko P, Ngo D, et al. Heat-directed tumor cell fusion. Hum Gene Ther 2003; 14: 447-4651.
25. Stetler-Stevenson WG, Aznavoorian S, Liotta LA, et al. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol 2003; 9: 541-573.
26. Jones L, Ghaneh P, Humphreys M, et al. The matrix metalloproteinases and their inhibitors in the treatment of pancreatic cancer. Ann NY Acad Sci 1999; 880: 288-307.
27. Moser TL, Young TN, Rodriguez GC, et al. Secretion of extracellular matrix-degrading proteinases is increased in epithelial ovarian carcinoma. Int J Cancer 1994; 56: 552-559.
28. Hewitt RE, Leach IH, Powe DG, et al. Distribution of collagenase and tissue inhibitor of metalloproteases (TIMP) in colorectal tumors. Int J Cancer 1991; 49: 666-672.
29. Ueno H, Nakamura H, Inoul M, et al. Expression and tissue localization of membrane-types 1, 2, and 3 matrix metalloproteases in human invasive breast carcinomas. Cancer Res 1997; 57: 2055-2060.
30. Lang FF, Bruner JM, Fuller GN, et al. Phase I trial of adenovirus-mediated p53 gene therapy for recurrent glioma: biological and clinical results. J Clin Oncol 2003; 21: 2508-2518.
31. Schneider RM, Medvedovska Y, Hartl I, et al. Directed evolution of retroviruses activable by tumor-associated matrix metalloproteases. Gene Ther 2003; 10: 1370-1380.